Urabe K, Aroca P, Tsukamoto K, Mascagna D, Palumbo A, Prota G, Hearing V J
Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Biochim Biophys Acta. 1994 Apr 28;1221(3):272-8. doi: 10.1016/0167-4889(94)90250-x.
The potential cytotoxicity of the melanogenic intermediates DOPA, (L-3,4-dihydroxyphenylalanine) and DHI (5,6-dihydroxyindole) has long been recognized and exploited as a targeting concept in experimental melanoma therapy. In recent years, however, a novel branchpoint in the melanin biosynthetic pathway has been shown to divert the metabolism of DOPAchrome to a carboxylated derivative termed DHICA (DHI-2-carboxylic acid) rather than to DHI. In order to evaluate the biological implications of this regulatory control, we have reexamined the inherent cytotoxicity of DHICA versus DHI on different cell lines. We found that under the usual conditions of the biological assay, the apparent cytotoxicity of the two indoles reflect their instability in the culture medium, the less stable DHI being generally more toxic than DHICA to melanoma cells and nonmelanocytic cells. Moreover, the observed cytotoxic effects increased with the time of incubation and were markedly reduced by the addition of catalase to the medium, suggesting that they were probably due to the generation of reactive oxygen species (particularly H2O2) during the autoxidation of the melanin precursors outside the cells. To circumvent this problem, we then tested the diacetylated derivatives of DHI and DHICA (DAI and DAICA) which are sufficiently stable until taken up into the cells whereupon they may be converted by endogenous esterases back to the parent indoles. Although DAI proved to be cytotoxic for nonmelanocytic cells, it had no detectable activity on melanoma cells, whereas DAICA showed no effect on any of the cells examined. These results, when combined with other studies, point to a reconsideration of the inherent cytotoxicity of the 5,6-dihydroxyindoles, as well as DOPA, to melanin producing cells.
黑色素生成中间体多巴(L-3,4-二羟基苯丙氨酸)和DHI(5,6-二羟基吲哚)的潜在细胞毒性早已得到认可,并被用作实验性黑色素瘤治疗中的一种靶向概念。然而,近年来,黑色素生物合成途径中的一个新分支点已被证明会使多巴色素的代谢转向一种称为DHICA(DHI-2-羧酸)的羧化衍生物,而不是DHI。为了评估这种调控的生物学意义,我们重新审视了DHICA与DHI对不同细胞系的内在细胞毒性。我们发现,在生物学测定的通常条件下,这两种吲哚的表观细胞毒性反映了它们在培养基中的不稳定性,稳定性较差的DHI对黑色素瘤细胞和非黑素细胞的毒性通常比DHICA更大。此外,观察到的细胞毒性作用随着孵育时间的延长而增加,并且通过向培养基中添加过氧化氢酶可显著降低,这表明它们可能是由于细胞外黑色素前体自氧化过程中活性氧(特别是H2O2)的产生所致。为了解决这个问题,我们随后测试了DHI和DHICA的二乙酰化衍生物(DAI和DAICA),它们在被细胞摄取之前足够稳定,随后可被内源性酯酶转化回母体吲哚。尽管DAI被证明对非黑素细胞具有细胞毒性,但对黑色素瘤细胞没有可检测到的活性,而DAICA对所检测的任何细胞均无影响。这些结果与其他研究相结合,表明需要重新考虑5,6-二羟基吲哚以及多巴对黑色素生成细胞的内在细胞毒性。